Modality
Gene Therapy
MOA
USP1i
Target
B7-H3
Pathway
DDR
RettSchizophreniaEwing Sarcoma
Development Pipeline
Preclinical
~Mar 2023
→ ~Jun 2024
Phase 1
Sep 2024
→ Dec 2031
Phase 1Current
NCT07640758
1,815 pts·Schizophrenia
2024-09→2031-12·Completed
1,815 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-035.7y awayInterim· Schizophrenia
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Complet…
Catalysts
Interim
2031-12-03 · 5.7y away
Schizophrenia
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07640758 | Phase 1 | Schizophrenia | Completed | 1815 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 |